As more pharmacologic treatment and research on child and adolescent psychiatric patients are conducted, the common problem of blood-drawing fears will need to be addressed. Avoidance of blood-drawing could jeopardize an individual's physical and mental health, and inhibit the collection of data aimed at furthering the study of psychiatric disorders in youth. This report describes the naturalistic application of specific techniques for managing severe blood-drawing fears in adolescent subjects undergoing a clinical trial. The adolescents (ages 12-18) were 44 consecutive school refusers with comorbid anxiety and major depressive disorders. Of the school-refusing adolescents, 27% (12 of 44) were observed to have a severe fear of blood-drawing. A management strategy comprised of providing information, distraction, supportive reassurance, and exposure appeared successful in managing the fears of blood-drawing in all of the adolescents, except two. These 2 adolescents refused to enter the treatment study due to a marked fear of blood-drawing. All 10 subjects who exhibited a fear of blood-drawing and were able to complete the initial blood test, using the interventions noted, were able to obtain subsequent venipunctures with minimal or no avoidance behavior. These preliminary findings suggest that blood-drawing fears can be effectively managed in most cases, though controlled studies of these interventions are needed.
Neuroleptic malignant syndrome (NMS) with serious complications is described for three adolescent males. Complications included extensive muscle necrosis with creatine phosphokinase (CPK) increased to 48,900 U/L, anticholinergic toxicity with fever and central anticholinergic syndrome, and brachial plexus injury, which mimicked an intracranial lesion. Such complications can interfere with prompt diagnosis of NMS and thereby contribute to its severity. Consistent with the phenomenology described for adults, all three adolescents presented with muscle rigidity, hyperthermia, elevated CPK, and a varied constellation of other abnormalities. Risk factors appeared to include male gender, underlying organicity, and the use of high-potency neuroleptic medication. All youths had been treated with haloperidol. Other factors may have contributed to the onset of NMS, including the final dosage, the rate of increase of haloperidol, the recent switch from a lower potency antipsychotic, and the concomitant use of other psychiatric medications. Treatment consisted of the discontinuation of haloperidol and supportive intervention. Additionally, all youths were treated with the dopamine agonists amantadme and bromocriptine, and one youth received the skeletal muscle relaxant dantroline. All recovered from their severe NMS episodes. Within a few days of NMS defervescence, two youths were rechallenged with a lower potency antipsychotic without NMS recurrence. These cases illustrate the complexity of neuroleptic side effects and the polymorphous presentation of NMS. They suggest that any deterioration in the clinical course of neuroleptic-treated adolescents should lead to inclusion of NMS in the differential diagnosis. Despite serious complications, full recovery from NMS is possible with aggressive supportive treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.